Skip to content Skip to Search
Skip navigation

Saudi deal ‘unlikely to cure Iraq’s pharma problems’

Unable to afford costly medicines, these Iraqi women buy traditional herbal remedies at a shop in Baghdad Reuters/Ahmed Saad
Unable to afford costly medicines, these Iraqi women buy traditional herbal remedies at a shop in Baghdad
  • Intellectual property law weak
  • Corruption ‘deep and wide’
  • Iraq imports 90% of medicine

Iraq has turned to Saudi Arabia to help it improve its healthcare industry and increase pharmaceutical manufacturing.

The ministries of health for both countries are collaborating to boost private healthcare in Iraq and foster partnerships to speed up the establishment of local pharmaceutical factories.

However analysts say the impact of the partnership will be limited by Iraq’s weak intellectual property protections and the lack of a transparent tendering process, which fuels corruption and the counterfeit drug market.

The collaboration is also expected to channel Saudi foreign direct investment into improving Iraq’s network of healthcare centres. 

The plan builds on discussions between Baghdad’s National Investment Commission and Riyadh’s Ministry of Industry and Minerals over the development of industrial investment zones throughout Iraq, including a specialised pharmaceutical zone in Yusufiyah. 

Neil Quilliam, associate fellow in the Mena programme at the think tank Chatham House, told AGBI that corrupt practices in Iraq’s pharma sector “run deep and wide” and serve the interests of too many embedded groups to be disrupted by Saudi-Iraqi co-operation. 

“Their collaboration will do little to encourage international businesses to invest in Iraq’s pharma sector,” he said.

Iraq’s high dependence on oil, alongside heightened security risks related to the conflict in the region, will also deter investments in the pharmaceutical market, according to analysts at BMI.

“Despite the positive initiative, Iraq’s pharmaceutical sector remains heavily underdeveloped, with medicine imports accounting for 90 percent of the market share,” BMI said. 

The non-import section of the market is monopolised by the state-owned SDI Samarra. Only a few private companies supply over-the-counter medicines and generic high-volume drugs such as paracetamol. 

“Iraq lacks both the infrastructure and trained workforce necessary to establish a self-sufficient pharmaceutical industry in the near to medium term,” BMI said. 

The pharma market in Iraq is projected to grow at a much slower rate than other economies in the Middle East and North Africa. 

By 2028, BMI forecasts that Iraq’s pharmaceutical industry will reach $2.6 billion, equal to an annual growth rate of 2.6 percent. The Mena average is 4.4 percent a year.

In Iraq, IP infringement cases are typically heard in commercial courts, which do not have the specialised resources to deal with the nuances of the law. This creates a “complex and challenging system” for domestic and multinational drugmakers, BMI said.

Last April, the US Trade Representative issued a report highlighting Iraq’s “burdensome” formalities for IP filing and extreme delays in processing.

BMI added: “Weak IP protection and a monopolised tendering process have led to a high level of corruption and informal payments to healthcare providers.”

As a result, it said, the price of a drug supplied by the same company can “fluctuate by 1,500 percent across Iraq”.

The counterfeit market has grown rapidly to “exploit pricing inconsistencies and maintain profitability, at the expense of drug quality and efficacy”.

Latest articles

Etihad Airways is opening new routes to Boston and Nairobi in 2024

ADQ explores potential listing of Etihad Airways

ADQ, the UAE’s sovereign wealth fund, is considering a potential listing of Etihad Airways, making it the first publicly traded airline in the GCC.  The fund has held discussions with banks on a possible floatation deal as soon as this year, Bloomberg reported, citing a source familiar with the deal. ADQ has been weighing the […]

The development by Al Fayha is the second mixed-use development announced for Muscat in a matter of days

Omani developer reveals Muscat mixed-use project

The Omani developer Al Fayha United Development company has launched a 13,000 square metre mixed-use project in Muscat. The Smart Home project in Al Ghala Heights, opposite Madinat Al Irfan, will include an apartment building comprising nine floors and a penthouse. Sheikh Saud bin Hamad al Ta’i, chairman of Al Faiha Development Company, said residential […]

Aramco buys out Chile’s fuel and lubricant retailer

Saudi Aramco, the world’s largest oil producer, has completed the acquisition of a 100 percent stake in Chile’s downstream fuel and lubricant retailer Esmax Distribución SpA (Esmax). The Chilean company owns and operates retail fuel stations, airport operations, fuel distribution terminals and a lubricant blending plant.  The transaction, which was announced in September 2023, is […]

People, Person, Groupshot

e&’s $6bn pledge to advance ‘affordable’ connectivity

The UAE’s e&, the telecommunications company formerly known as Etisalat, has committed $6 billion to improve network connectivity and digital services across its 16 operating countries in Africa, Asia, and the Middle East. The investment pledge was made to the International Telecommunication Union’s (ITU) Partner2Connect Digital Coalition, which will help drive technological advancement, infrastructure development, […]